Glaxosmithkline Share Price (GSK)

Show Chart Filters
Time period:
Moving Average:
Compare to:
Price 1,658.20on 21-02-2020 at 16:30:00
Change 8.20 0.50%
Buy 1,655.00
Sell 1,654.40
Buy / Sell GSK Shares
Sponsored Financial Content
Last Trade: Sell 75 at 1,647.302p
Day's Volume: 6,573,496
Last Close: 1,650.00p
Open: 1,644.00p
ISIN: GB0009252882
Day's Range 1,640.00p - 1,658.80p
52wk Range: 1,485.20p - 1,857.00p
Market Capitalisation: £83,182m
VWAP: 0.00p
Shares in Issue: 5,016m

Recent Trades History Glaxosmithkline (GSK)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell*751,647.302Ordinary
18:45:01 - 21-Feb-20
Sell*43,3701,647.784Ordinary
18:45:01 - 21-Feb-20
Sell*1,6921,646.399Ordinary
Delayed publication
10:17:16 - 21-Feb-20
Buy*32,2431,658.20Ordinary
Delayed publication
17:31:16 - 21-Feb-20
Buy*35,4821,657.804Ordinary
17:52:23 - 21-Feb-20
Buy*96,8061,658.20Ordinary
17:40:31 - 21-Feb-20
Buy*3,2051,657.483Ordinary
17:27:35 - 21-Feb-20
Buy*23,2171,658.084Ordinary
17:16:40 - 21-Feb-20
Sell*5681,652.551Ordinary
17:14:32 - 21-Feb-20
Sell*9,5931,650.463Ordinary
17:12:21 - 21-Feb-20

Share Price History for Glaxosmithkline

Time period:
to
Date Open High Low Close
20th Feb 2020 (Thu)1,650.201,660.601,643.001,648.80
19th Feb 2020 (Wed)1,669.801,688.201,667.601,677.50
18th Feb 2020 (Tue)1,651.801,668.401,640.401,665.90
17th Feb 2020 (Mon)1,678.601,678.601,658.601,661.10
14th Feb 2020 (Fri)1,682.201,682.601,662.401,666.80
13th Feb 2020 (Thu)1,692.201,694.801,663.201,677.80
12th Feb 2020 (Wed)1,703.001,704.601,690.401,696.00
11th Feb 2020 (Tue)1,726.001,742.601,703.401,710.00
10th Feb 2020 (Mon)1,697.001,718.801,690.801,718.60
7th Feb 2020 (Fri)1,696.201,704.801,689.001,701.30
6th Feb 2020 (Thu)1,726.601,735.801,670.201,689.90
5th Feb 2020 (Wed)1,803.801,847.001,739.601,744.30
4th Feb 2020 (Tue)1,818.001,826.801,807.401,817.40
3rd Feb 2020 (Mon)1,784.001,811.001,778.001,804.40
31st Jan 2020 (Fri)1,793.001,801.601,782.001,793.50
30th Jan 2020 (Thu)1,807.001,824.801,789.801,793.50
29th Jan 2020 (Wed)1,797.201,815.801,791.401,814.90
28th Jan 2020 (Tue)1,786.001,799.201,778.801,792.90
27th Jan 2020 (Mon)1,795.001,808.601,771.601,782.50
24th Jan 2020 (Fri)1,823.601,857.001,821.401,824.80
23rd Jan 2020 (Thu)1,823.801,831.601,814.001,823.30

GSK - Glaxosmithkline Investor Summary

GlaxoSmithKline, or 'GSK', is one of the world's leading pharmaceutical companies researching medicines and vacines alike for the World Health Organization's three priority diseases: HIV/AIDS, Malaria and Tuberculosis. With an estimated 7% of the world's pharmaceutical market under its wing, GSK remains one of the industry leaders globally but remains committed to the research and application of life changing and marketable drugs.

If investing in science seems a little confusing and unpredictable then perhaps some of GSK's over-the-counter and more recognisable products will help to convince; these include Gaviscon and Panadol, smoking control products such as Nicorette/Niquitin and nutritional healthcare drinks such as Lucozade, Ribena and Horlicks.

On 23rd January 2009, GSK announced that it had signed an agreement with UCB S.A to acquire its marketed product portfolio in certain parts of the Middle East, Africa, Latin America and Asia Pacific, for a cash consideration of some £484 million. President of Emerging Markets at GSK, Abbas Hussain, said that "This acquisition will strengthen and expand GSK's product portfolio in these countries, helping us to meet the needs of patients, particularly in the areas of epilepsy and respiratory." Under the agreement, GSK acquires several leading pharmaceutical brands and investors will be interested to know that the commercial operations and product distribution rights included represent approximately 3-4% of UCB's 2008 expected revenue of at least £3.09 billion. At the time of Mr Hussain speaking, share prices for GSK were steady at 1,226.00p with a "strong buy" recommendation from brokers.

News about Glaxosmithkline (GSK)

Director Deals - GlaxoSmithKline PLC (GSK)

News - Thursday, February 20, 2020

Emma Walmsley, Chief Executive Officer, exercised 62,036 shares in the company o......

Director Deals - GlaxoSmithKline PLC (GSK)

News - Thursday, February 20, 2020

Emma Walmsley, Chief Executive Officer, exercised 62,036 shares in the company o......

FTSE 100 Latest
Value7,403.92
Change-32.72


Login to your account

Forgot Password?

Not Registered